Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation

Ähnliche Einträge

• The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities
  von: Matthew M. Abernathy, et al.
  Veröffentlicht: (2024)
• Does Changing the Context of Use Change the Value Proposition of CiPA ?
  von: Charles T. Benson, et al.
  Veröffentlicht: (2026)
• The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency
  von: Elodie Baumfeld Andre, et al.
  Veröffentlicht: (2024)
• Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
  von: Minji Kim, et al.
  Veröffentlicht: (2026)
• Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated Costs
  von: Hyunwoo Koo, et al.
  Veröffentlicht: (2025)